Esperion Therapeutics Inc (ESPR)

Esperion Therapeutics Inc. (ESPR) stock dropped by 21.23% due to the announcement of a $125 million amendment to the collaboration between Esperion Therapeutics and Daiichi Sankyo Europe GmbH (DSE), the European headquarters of Daiichi Sankyo Co., Ltd., a Japanese pharmaceutical company.

• Collaboration Amendment Details: The amendment involved DSE paying Esperion $100 million in anticipation of a regulatory approval by the European Medicines Agency (EMA) and an additional $25 million payment after EMA's decision. The parties also resolved a legal action. Additionally, the agreement included a transition of manufacturing responsibilities to DSE, potential collaboration expansion for a new product, and DSE leading regulatory communications with EMA.
• Impact on Stock Price: The stock's significant decline likely resulted from investor reactions to the financial and operational changes arising from the collaboration amendment. The resolution and adjustments could have implications for Esperion Therapeutics' future business prospects, influencing the stock's performance.